Navigation Links
Type 1 diabetes may result from good genes behaving badly
Date:9/19/2008

WHAT: New research from Stanford University scientists suggests that type 1 diabetes, an autoimmune disease that develops in children and young adults, may not be due to bad genes but rather to good genes behaving badly.

Because type 1 diabetes typically runs in families, scientists have looked for inborn genetic errors or gene variants passed on from generation to generation. Although this search has failed to find a single type 1 diabetes gene, many candidate type 1 diabetes susceptibility genes have been identified. These susceptibility genes, located in a region known as the major histocompatibility complex (MHC), help the body distinguish its own cells and tissues from those that are foreign.

Studies in identical twins, however, reveal that the situation is more complicated: often one twin develops type 1 diabetes while the other twin remains disease-free. This pattern of good luck/bad luck led researchers at Stanford to examine whether genetically at-risk individuals respond differently to environmental stimuli. In some cases, the immune system will respond in a benign fashion, while in other cases it will begin an inflammatory response that can ultimately lead to diabetes. The critical difference between health and disease might thus reside not in an individual's genetic blueprint but in how those genes are "expressed"--that is, how the translation of genetic information into proteins or RNA is switched on and off.

In a study supported by the National Institute of Allergy and Infectious Diseases, (NIAID) part of the National Institutes of Health, the Stanford team, led by C. Garrison Fathman, M.D., studied differences in gene expression between two groups of mice. The first group, non-obese diabetic mice, spontaneously develop type 1 diabetes. The second group, mice genetically identical to the first group except for their MHC genes, do not develop the disease. The researchers looked at gene expression in three different tissues in the diabetic and non-diabetic mice at separate times after birth. In the first few weeks of life, they found an explosion of changes in gene expression in the pancreatic lymph nodes, spleen and circulating blood cells of the diabetic mice compared with those in the non-diabetic mice. At 8 weeks, this activity had quieted down. But several weeks later, when the mice were 12 weeks old, a second explosion of changes in gene expression occurred in the diabetic mice in all three tissues examined: pancreatic lymph nodes, spleen and blood cells.

According to Dr. Fathman, the results suggest that type 1 diabetes may not result from genetic mutations but from differences in how normal genes and gene variants are turned on and off during disease progression. In addition to identifying altered genes that may indicate potential avenues for therapeutic or preventive treatments, the authors also found patterns of coordinated gene expression that may prove useful as biomarkers of disease onset or progression.


'/>"/>

Contact: Bill Crews
crewsw@niaid.nih.gov
301-402-1663
NIH/National Institute of Allergy and Infectious Diseases
Source:Eurekalert

Related medicine news :

1. Diabetes Spectrum Reports a Study Assessing the i-port(R) Injection Port for Administration of Insulin
2. Session highlights of the 1st World Congress on Interventional Therapies for Type 2 Diabetes
3. Weight-Loss Surgery Weighed as Diabetes Rx
4. American Diabetes Association Announces New Latino Diabetes Toolkit
5. American Diabetes Association Kicks 0ff Hispanic Heritage Month
6. Community-based diabetes prevention program shows promise
7. Once-Weekly Diabetes Drug Boosts Blood Sugar Control
8. Early trigger for type-1 diabetes found in mice, Stanford scientists report
9. Endocrinologists and surgeons join forces to fight type 2 diabetes
10. Nutraceuticals could prevent diabetes
11. Amylin Pharmaceuticals Diabetes Drug Byetta the Focus of California Lawsuit
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/7/2016)... ... ... A quote from Dr. Edward Hallowell, host of CRN International’s “Distraction” podcast ... glimpse into the mind of those people with ADHD. , Dr. Hallowell, a child ... people with ADHD as having “Ferrari engines for a brain, with bicycle brakes.” , ...
(Date:12/7/2016)... ... December 07, 2016 , ... The Cliff ... located in South Lyon, Dewitt, Williamston, East Lansing, Ann Arbor, and Farmington Hills, ... treatment for a brain tumor. , Jason Bauer and his family are longtime ...
(Date:12/7/2016)... ... December 07, 2016 , ... A. Kevin Spann Insurance, a New York-based firm ... Boroughs, is launching a charity drive to raise funds that will benefit the Marine ... of marines and Navy FMF Corpsmen. Working closely with the MCL, the A. Kevin ...
(Date:12/7/2016)... ... December 07, 2016 , ... Delete® - Tattoo Removal and Laser Salon Offers ... Season. Save Up To 33% Off Botox® and Juvederm® Products Now Through December 31, ... with Delightful Deals on Botox® and Juvederm® just in time for the ...
(Date:12/7/2016)... ... December 07, 2016 , ... ... BOC Business Brilliance Awards under the Best New Product Launch category. Gensuite’s entry ... through user experience. , BOC Global Events & Training Group is a professional ...
Breaking Medicine News(10 mins):
(Date:12/7/2016)... -- According to responses from U.S. oncologists that participated in ... with non-small cell lung cancer (NSCLC), treatment decisions are made ... status. The findings of the survey were presented today as ... ) at the 2016 World Conference on Lung Cancer (WCLC) ... survey results revealed an overall high rate of EGFR mutation ...
(Date:12/7/2016)... ALTO, Calif. , Dec. 7, 2016  Varian ... an update to its previously announced plans to separate ... be executed via a tax-free distribution to Varian stockholders ... stand-alone public company that will hold the Imaging Components ... expected to be executed by the end of January ...
(Date:12/7/2016)... , Dec. 7, 2016 Boehringer ... trial in patients with unresectable malignant pleural mesothelioma ... (PFS). The data, presented at the 17 th ... Vienna , showed nintedanib plus ... placebo plus pemetrexed/cisplatin, with a significantly improved PFS ...
Breaking Medicine Technology: